S. Ruggiero, T. Dodson, and L. Assael, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate?related osteonecrosis of the jaws??2009 update, J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg, vol.67, pp.2-12, 2009.

J. Wessel, T. Dodson, and A. Zavras, Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control Study, Journal of Oral and Maxillofacial Surgery, vol.66, issue.4, pp.625-631, 2008.
DOI : 10.1016/j.joms.2007.11.032

F. Basso, S. Turrioni, A. Hebling, J. De-souza-costa, and C. , Zoledronic Acid Inhibits Human Osteoblast Activities, Gerontology, vol.59, issue.6, pp.534-541, 2013.
DOI : 10.1159/000351194

H. Mawardi, G. Giro, and M. Kajiya, A Role of Oral Bacteria in Bisphosphonate-induced Osteonecrosis of the Jaw, Journal of Dental Research, vol.302, issue.11, pp.1339-1345, 2011.
DOI : 10.1124/jpet.102.035295

R. Kim, R. Lee, and D. Williams, Bisphosphonates Induce Senescence in Normal Human Oral Keratinocytes, Journal of Dental Research, vol.24, issue.6, pp.810-816, 2011.
DOI : 10.1016/S8756-3282(98)00144-6
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144120/pdf

M. Allen and D. Burr, The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data, Journal of Oral and Maxillofacial Surgery, vol.67, issue.5, pp.61-70, 2009.
DOI : 10.1016/j.joms.2009.01.007

N. Sims and T. Martin, Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit, BoneKEy Reports, vol.3, 2014.
DOI : 10.1038/bonekey.2013.215

N. Sims, K. Ng, N. Sakagami, N. Amizuka, and M. Li, Implications of Osteoblast-Osteoclast Interactions in the Management of Osteoporosis by Antiresorptive Agents Denosumab and Odanacatib, Current Osteoporosis Reports, vol.26, issue.Suppl 2, pp.98-106688, 1993.
DOI : 10.1002/jbmr.335

P. Lesclous, A. Najm, S. Carrel, and J. , Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?, Bone, vol.45, issue.5, pp.843-852, 2009.
DOI : 10.1016/j.bone.2009.07.011

F. Koch, C. Merkel, and B. Al?nawas, Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner ??? A quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2, Journal of Cranio-Maxillofacial Surgery, vol.39, issue.8, pp.562-569, 2011.
DOI : 10.1016/j.jcms.2010.10.007

F. Manzano?moreno, J. Ramos?torrecillas, D. Luna?bertos, and E. , High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis, Journal of Cranio-Maxillofacial Surgery, vol.43, issue.3, pp.396-401, 2015.
DOI : 10.1016/j.jcms.2014.12.008

S. Pozzi, S. Vallet, and S. Mukherjee, High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties, Clinical Cancer Research, vol.15, issue.18, pp.5829-5839, 2009.
DOI : 10.1158/1078-0432.CCR-09-0426
URL : http://clincancerres.aacrjournals.org/content/clincanres/15/18/5829.full.pdf

B. Gobin, S. Battaglia, and R. Lanel, NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate, Cancer Letters, vol.344, issue.2, pp.291-298, 2014.
DOI : 10.1016/j.canlet.2013.11.017
URL : https://hal.archives-ouvertes.fr/inserm-01644806

B. Gobin, M. Huin, and F. Lamoureux, BYL719, a new ??-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma, International Journal of Cancer, vol.70, issue.Supp 1, 2014.
DOI : 10.1158/0008-5472.CAN-09-4172

F. Lamoureux, M. Baud-'huin, R. Calleja, and L. , Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle, Nature Communications, vol.128, pp.10-4511, 1038.
DOI : 10.1002/ijc.25776

M. Allen and D. Burr, Mandible Matrix Necrosis in Beagle Dogs After 3 Years of Daily Oral Bisphosphonate Treatment, Journal of Oral and Maxillofacial Surgery, vol.66, issue.5, pp.987-994, 2008.
DOI : 10.1016/j.joms.2008.01.038

D. Heymann, Editorial [Hot topic: Bisphosphonates and Bone Diseases: Past, Present and Future (Guest Editor: Dominique HEYMANN)], Current Pharmaceutical Design, vol.16, issue.27, pp.2948-2949, 2010.
DOI : 10.2174/138161210793563572

D. Heymann, B. Ory, and F. Gouin, Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-343, 2004.
DOI : 10.1016/j.molmed.2004.05.007

L. Goff, B. Guillot, P. Glémarec, and J. , A Comparison Between Bisphosphonates and Other Treatments for Osteoporosis, Current Pharmaceutical Design, vol.16, issue.27, pp.3037-3044, 2010.
DOI : 10.2174/138161210793563563

M. Pazianas, Osteonecrosis of the Jaw and the Role of Macrophages, JNCI Journal of the National Cancer Institute, vol.103, issue.3, pp.232-272, 2011.
DOI : 10.1093/jnci/djq516

Y. Bi, Y. Gao, and D. Ehirchiou, Bisphosphonates Cause Osteonecrosis of the Jaw-Like Disease in Mice, The American Journal of Pathology, vol.177, issue.1, 2010.
DOI : 10.2353/ajpath.2010.090592

N. Raje, S. Woo, and K. Hande, Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw, Clinical Cancer Research, vol.14, issue.8, pp.2387-2395, 2008.
DOI : 10.1158/1078-0432.CCR-07-1430

R. Marx, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic, Journal of Oral and Maxillofacial Surgery, vol.61, issue.9, pp.1115-1117, 2003.
DOI : 10.1016/S0278-2391(03)00720-1

K. Marino, I. Zakhary, and R. Abdelsayed, Development of a Rat Model of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ), Journal of Oral Implantology, vol.38, issue.S1, pp.10-1563, 2011.
DOI : 10.1563/AAID-JOI-D-11-00057

S. Okazaki, Y. Nishitani, and S. Nagoya, Femoral head osteonecrosis can be caused by disruption of the systemic immune response via the toll-like receptor 4 signalling pathway, Rheumatology, vol.48, issue.3, pp.227-232, 2009.
DOI : 10.1093/rheumatology/ken462

T. Aghaloo, B. Kang, and E. Sung, Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat, Journal of Bone and Mineral Research, vol.22, issue.(5 Suppl), pp.1871-1882, 2011.
DOI : 10.1007/s00198-010-1177-6

R. Marx, Y. Sawatari, M. Fortin, and V. Broumand, Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment, Journal of Oral and Maxillofacial Surgery, vol.63, issue.11, pp.1567-1575, 2005.
DOI : 10.1016/j.joms.2005.07.010

M. Allen, Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment, Expert Opinion on Drug Metabolism & Toxicology, vol.1, issue.11, pp.1371-1378, 2008.
DOI : 10.1359/jbmr.070504

J. Aguirre, M. Akhter, and D. Kimmel, Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis, Journal of Bone and Mineral Research, vol.28, issue.2, pp.2130-2143, 2012.
DOI : 10.1007/s00774-009-0128-9

A. Hoff, B. Toth, and K. Altundag, Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates, Journal of Bone and Mineral Research, vol.90, issue.Suppl 1, pp.826-836, 2008.
DOI : 10.4158/EP.12.1.48

F. Daubiné, L. Gall, C. Gasser, and J. , Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone Metastasis, JNCI Journal of the National Cancer Institute, vol.99, issue.4, pp.322-330, 2007.
DOI : 10.1093/jnci/djk054

D. Williams, C. Lee, and T. Kim, Impaired Bone Resorption and Woven Bone Formation Are Associated with Development of Osteonecrosis of the Jaw-Like Lesions by Bisphosphonate and Anti???Receptor Activator of NF-??B Ligand Antibody in Mice, The American Journal of Pathology, vol.184, issue.11
DOI : 10.1016/j.ajpath.2014.07.010

R. Doh, H. Park, and Y. Rhee, Teriparatide Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw Associated With Dental Implants, Implant Dentistry, vol.24, pp.222-226, 2015.
DOI : 10.1097/ID.0000000000000232

A. Khan, A. Morrison, and S. Ruggiero, Response to Comments on ???Diagnosis and Management of Osteoporosis of the Jaw: A Systematic Review and International Consensus???, Journal of Bone and Mineral Research, vol.30, issue.10, 2015.
DOI : 10.1002/jbmr.2524

R. Weinstein, P. Roberson, and S. Manolagas, Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy, New England Journal of Medicine, vol.360, issue.1, pp.53-62, 2009.
DOI : 10.1056/NEJMoa0802633

B. Jobke, M. Pfeifer, and H. Minne, Teriparatide Following Bisphosphonates: Initial and Long-Term Effects on Microarchitecture and Bone Remodeling at the Human Iliac Crest, Connective Tissue Research, vol.21, issue.1, pp.46-54, 2009.
DOI : 10.1038/ki.1994.328

B. Jobke, A. Roelofs, K. Thompson, S. Gordon, and M. Rogers, Giant osteoclast formation and long?term oral bisphosphonate therapy Molecular Mechanisms of Action of Bisphosphonates: Current Status, N Engl J Med Clin Cancer Res, vol.360, issue.12, pp.1676-1677, 2006.

H. Kim, Osteonecrosis and osteonecrosis of the jaw (ONJ), J Musculoskelet Neuronal Interact, vol.7, pp.348-349, 2007.

T. Hansen, M. Kunkel, A. Weber, J. Kirkpatrick, and C. , Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis, Journal of Oral Pathology and Medicine, vol.64, issue.3, pp.155-160, 2006.
DOI : 10.1111/j.1600-0714.2004.00269.x

D. Santini, B. Vincenzi, and G. Dicuonzo, Zoledronic Acid Induces Significant and Long?Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients, Clin Cancer Res, vol.9, pp.2893-2897, 2003.

C. Estilo, M. Fornier, and A. Farooki, Osteonecrosis of the Jaw Related to Bevacizumab, Journal of Clinical Oncology, vol.26, issue.24, pp.4037-4038, 2008.
DOI : 10.1200/JCO.2007.15.5424

G. Lescaille, A. Coudert, and V. Baaroun, Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients, Bone, vol.58, 2014.
DOI : 10.1016/j.bone.2013.10.002

T. Ziebart, A. Pabst, and M. Klein, Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro, Clinical Oral Investigations, vol.237, issue.3, pp.105-111, 2011.
DOI : 10.1006/bbrc.1997.7145

C. Walter, A. Pabst, and T. Ziebart, Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro, Oral Diseases, vol.65, issue.Suppl, pp.194-199, 2011.
DOI : 10.1016/j.joms.2007.03.006
URL : https://hal.archives-ouvertes.fr/hal-00599899

J. Wood, K. Bonjean, and S. Ruetz, Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid, Journal of Pharmacology and Experimental Therapeutics, vol.302, issue.3, 2002.
DOI : 10.1124/jpet.102.035295

P. Fournier, S. Boissier, and S. Filleur, Bisphosphonates inhibit angiogenesis in vitro and testosterone?stimulated vascular regrowth in the ventral prostate in castrated rats, Cancer Res, vol.62, pp.6538-6544, 2002.

V. Stresing, P. Fournier, and A. Bellahcène, Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase, Bone, vol.48, issue.2, pp.259-266, 2011.
DOI : 10.1016/j.bone.2010.09.035

A. Pabst, T. Ziebart, and M. Ackermann, Bisphosphonates??? antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay, Clinical Oral Investigations, vol.76, issue.2, pp.1015-1022, 2014.
DOI : 10.1159/000201931

P. Guihard, Y. Danger, and B. Brounais, Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes, Macrophages Depends on Oncostatin M Signaling. STEM CELLS, vol.30, pp.762-772, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00668995

V. Nicolaidou, M. Wong, and A. Redpath, Monocytes Induce STAT3 Activation in Human Mesenchymal Stem Cells to Promote Osteoblast Formation, PLoS ONE, vol.125, issue.7, 2012.
DOI : 10.1371/journal.pone.0039871.s003